ORIGINAL ARTICLE

Levocetirizine Dihydrochloride-Loaded Chitosan Nanoparticles: Formulation and *In Vitro* Evaluation

Levosetirizin Dihidroklorür Yüklü Kitosan Nanopartikülleri: Formülasyonu ve *İn Vitro* Değerlendirilmesi

Ⓘ Gülsel YURTDAŞ KIRIMLIOĞLU*, Ⓘ A. Alper ÖZTÜRK

Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Eskişehir, Turkey

ABSTRACT

Objectives: The aim of the present study was to formulate levocetirizine hydrochloride (LCD)-loaded chitosan nanoparticles at submicron level with high entrapment efficiency and prolonged effect for optimizing the plasma drug concentration enhancing bioavailability.

Materials and Methods: LCD was successfully incorporated into chitosan nanoparticles by spray drying for the purpose of oral application. *In vitro* characteristics were evaluated in detail.

Results: LCD was successfully loaded into the polymeric matrices by spray drying. Characterization of the nanoparticles including encapsulation efficiency, particle size, zeta potential, morphology, polydispersity index, solid-state characterizations, and LCD quantification by high performance liquid chromatography was performed. The release pattern of LCD from the nanoparticles was determined using a dialysis tube in simulated intestinal fluid (pH 6.8). *In vitro* release profiles indicated prolonged release of LCD from the nanoparticles that followed the Korsmeyer-Peppas kinetic model.

Conclusion: Chitosan-based LCD-loaded polymeric nanoparticles appear to be a promising drug delivery system for the active agent.

Key words: Levocetirizine dihydrochloride, chitosan, polymeric nanoparticle, spray drying

ÖZ

Amaç: Bu çalışmanın amacı, biyoyararlanımı iyileştirerek plazma ilaç konsantrasyonunu optimize etmek için uzatılmış etkiye ve yüksek yükleme kapasitesine sahip, mikron altı düzeyde levosetirizin dihidroklorür (LCD) yüklü kitosan nanopartijkülleri formüle etmektir.

Gereç ve Yöntemler: Bu çalışmada LCD, oral uygulama amacı ile kitosan nanopartiküllerine püskürterek kurutma yöntemi kullanılarak yüklenmiştir. Nanopartiküllerin *in vitro* karakteristik özellikleri detaylıca incelenmiştir.

Bulgular: LCD püskürterek kurutma yöntemi ile polimerik matrise başarıyla yüklenmiştir. Nanopartiküllerin karakterizasyonu yüklenme etkinliği, parçacık büyüklüğü, zeta potansiyel, morfoloji, polidisperslik indisi ve yüksek basınçlı sıvı kromatografisi ile LCD tayini dahil olmak üzere yapılmıştır. Nanopartiküllerden LCD salımı simüle edilmiş bağırsak vasatında (pH 6,8) diyaliz tübü kullanılarak gerçekleştirilmiştir. Nanopartiküllerden LCD salımına ait *in vitro* salım profilleri Korsmeyer-Peppas modeline uygunluk göstererek uzatılmış salım göstermiştir.

Sonuç: Kitosan bazlı LCD yüklü polimerik nanopartiküllerin etkin madde için umut verici bir ilaç taşıyıcı sistem olduğu sonucuna varılabilir.

Anahtar kelimeler: Levosetirizin dihidroklorür, kitosan, polimerik nanopartikül, püskürterek kurutma

INTRODUCTION

Levocetirizine dihydrochloride (LCD) is an orally active, third generation nonsedative antihistaminic agent widely used in the treatment of chronic idiopathic urticaria, seasonal allergic rhinitis, and hay fever.[1,2] It has more affinity for H_1 receptors when compared to cetirizine hydrochloride (CD).[1] LCD is rapidly and extensively absorbed after oral administration, with the peak plasma concentration attained in 0.9-1 h.[3] LCD undergoes a low degree of first pass metabolism in the liver; it is metabolized to a limited extent by oxidative dealkylation to metabolite negligible antihistaminic activity. It is approximately 93% bound to plasma proteins and has a plasma elimination half-life of 8-9 h that does not change with multiple dosing.[4] The fast disintegration behavior of conventional LCD formulations may result in initial burst-released kinetics, permitting the drug to be absorbed very quickly and resulting in high serum concentrations. Under these conditions, local irritation to gastrointestinal (GI) mucous membranes and other side effects such as drowsiness, tiredness, dry mouth, fever, cough, oculogyric crisis, and somnolence are inevitable.[2,5] Therefore, it is desirable to design and develop a rational delivery system for LCD. Many efforts towards designing CD and LCD (active enantiomer of CD) sustained delivery systems by encapsulating, forming flexible vesicles, microparticles, and nanoparticles were made during the last decade.[2,4-6] Nanoparticles have attracted considerable attention due to their advantageous properties such as decreased particle size, increased surface area, enhanced reactivity, promoted drug release, reformed targeting, reduced toxicity, and improved sustained-release efficacy.[7] Surface charges of nanoparticles have a significant effect on internalization with cells and also on their uptake. Positively charged nanoparticles seem to allow a higher extent of internalization apparently as a consequence of ionic interactions established between cationic nanoparticles and negatively charged membranes.[8] Chitosan is a polycationic polymer that is a naturally occurring polysaccharide found abundantly in marine crustaceans, insects, and fungi.[9,10] Chitosan is composed of 2-amino-2-deoxy-β-D-glucan combined with glycosidic linkages.[11] Positively charged amino groups of polymer interact with negatively charged biological membranes, ensuring a mucoadhesive character of the chitosan matrices.[12] Chitosan is one of the most extensively studied materials in the pharmaceutical field. Properties such as biodegradability, low toxicity, good biocompatibility, and no risk of accumulation/retention in the body make it suitable for use in biomedical and pharmaceutical formulations.[13] Spray drying is a single-step, cheap, continuous, and scalable process that enables the production of particles with controlled size and morphological aspects.[14] Spray drying also eliminates the addition of crosslinking agent and minimizes the swelling of chitosan-based nanoparticles.[15] Therefore, spray drying technology was utilized in the present study for the formulation of cationic nanoparticles using the advantages of the method. Our study may provide valuable information for the design and development of new LCD-loaded controlled-release dosage forms. The aim of the present study was to formulate positively charged LCD-loaded nanoparticles at submicron level with high encapsulation efficiency (EE), reduced local irritation to GI mucous membranes and other side effects, and prolonged plasma level drug concentration enhancing the bioavailability and protection of sensitive drugs against light thus improving their stability.

MATERIALS AND METHODS

Materials

The LCD was a kind gift from Neutec (İstanbul, Turkey). Chitosan (low molecular weight with 20-200 mPas.s viscosity) was purchased from Sigma (Steinheim, Germany). All other reagents used were of analytical grade.

Preparation of nanoparticles

Chitosan nanoparticles were prepared using a mini spray dryer (B-190, Buchi, Switzerland). The spray dryer was connected to an Inert Loop B-295 (Buchi, Switzerland) due to the organic solvent. Carbon dioxide gas was used at a flow rate of 120 L.min^{-1}. The residual oxygen level in the system was kept below 4%. When preparing particulate systems by spray drying, it has to be kept in the mind that production parameters such as size of nozzle, feeding pump rate, inlet temperature, and compressed air flow rate affect particle size.[15,16] It was reported that smaller particles are formed with a lower feeding pump rate and smaller nozzle size. In addition, smaller particles are formed with greater volume of air input where particle size is not dependent on inlet temperature in the range of 120-180°C.[15] Therefore, the inlet temperature was maintained at 120°C using the slowest pump rate that can spray the solution.

Accurately weighed chitosan (1 g) was dissolved in acetic acid solution (2% v/v, 120 mL). Ethanol (96% v/v, 120 mL) was added to the acidic solution in order to decrease the viscosity of the chitosan solution. LCD was added to the mixture under constant stirrer speed (300 rpm) on a magnetic stirrer. The final clear solution was then spray dried with an inlet temperature of 120±1°C and outlet temperature of 60±5°C and delivered to a drying zone via a 4 μm nozzle. White dry powders were obtained and kept in tightly closed vials at room temperature until being analyzed. Placebo nanoparticles were prepared as described above without the addition of active agent.

The spray-drying conditions are shown in Table 1.

Characterization of nanoparticles

Morphology

The particle shape and surface characteristics of the freshly prepared nanoparticle formulations and LCD were investigated by scanning electron microscope (SEM) (Hitachi TM3030Plus Tabletop Microscope, Japan) at 25±2°C. Samples were coated with a thin layer of gold under argon to avoid charging under the electron beam.

Table 1. Spray-drying conditions

Inlet temperature	Outlet temperature	Flow rate mL/min	Pump control level	Aspirator control level
120°C	60°C	450	3	3

Particle size and zeta potential

Particle size, polydispersity index (PI), and zeta potential measurements were carried out on freshly prepared samples using a Malvern Nano ZS (Zetasizer Nano Series, Malvern, Worcestershire, UK). Samples of all nanoparticles were dispersed in double distilled water (adjusted to a constant conductivity of 50 µS.cm^{-1} using 0.9% NaCl) just prior to analyses. All analyses were repeated in triplicate at 25±2°C. The data obtained were evaluated by span values calculated using volume distribution as diameter (d) values of 10%, 50%, and 90%. The diameter values indicate the percentage of particles possessing a diameter equal to or lower than the given value. The span value is a statistical parameter useful for evaluating the particle size distribution and calculated by the following equation:[17]

Span value=[d(90)-d(10)]/d(50) (1)

Differential scanning calorimetry

Structural and crystallinity changes in LCD and the polymer due to the thermal impacts during the formulation steps were evaluated using differential scanning calorimetry (DSC) (DSC-60, Shimadzu Scientific Instruments, Columbia, MI, USA). Analyses were performed under nitrogen at a flow rate of 50 mL.min^{-1} at 30-250°C with a rate of increase of 10°C.min^{-1}.

Fourier transform infrared spectrophotometry

Fourier transform infrared (FT-IR) analysis spectra were recorded using a Shimadzu IR Prestige-21 (Shimadzu Corporation, Kyoto, Japan) at the wavelength range of 4000-500 cm^{-1}.

Nuclear magnetic resonance spectroscopy

Nuclear magnetic resonance (NMR) spectroscopy (^{1}H-NMR) analyses were performed using an UltraShield™ CPMAS NMR (Bruker, Rheinstetten, Germany). Samples were prepared by dissolving nanoparticles in deuterated dimethyl sulfoxide. Pure chitosan and LCD were analyzed by DSC, FT-IR, and ^{1}H-NMR and were used as reference evaluating the interaction between polymer and LCD.

Determination of LCD

High performance liquid chromatography (HPLC) was used for the determination of LCD. A Shimadzu 20-A (Tokyo, Japan) equipped with a reversed phase Nucleosil 120-5 column (column diameter: 4.6 mm, column length: 250 mm, C$_{18}$ gravity, 5 µm) was used. Acetonitrile: water: 1 M sulfuric acid (93:66:4, v/v/v) was used as mobile phase with a flow rate of 1 mL.min^{-1}; 20 µL constant amount of samples injected via an automatic injector (Shimadzu, Tokyo, Japan) was used and a photodiode detector was used at 230 nm.[18] Column temperature was set to 30°C. Validation studies were carried out for data reliability.

Encapsulation efficiency

In order to determine the amount of LCD in drug-loaded nanoparticles, drug EE was determined by validated HPLC method. Accurately weighed nanoparticles (5 mg) were dispersed in acetonitrile (1 mL), vortexed for 1 min, and centrifuged at 2500 rpm for 5 min for the determination of LCD

remaining on the chitosan sphere surface (LCD$_s$).[12] The quantity of LCD encapsulated in nanoparticles was calculated as the difference between the amount initially added (LCD$_t$) and the LCD$_s$.[5] Each experiment was repeated three times.

EE %=[(LCD$_t$-LCD$_s$)/LCD$_t$]×100 (2)

In vitro drug release

A dialysis membrane method was used to identify the release behavior of nanoparticles. *In vitro* release profiles of LCD were investigated in freshly prepared simulated intestinal fluid (SIF, pH 6.8) over 72 h. Briefly, drug-loaded nanoparticles containing 1.5 mg of LCD were put in dialysis bags (with a molecular cut-off 12-14 kD, Sigma) and capped with closures. The bags were immersed into dissolution medium containing 80 mL of SIF at 37±1°C on a water bath using a continuous magnetic stirring rate of 100 rpm.[7] Next 1-mL samples were withdrawn at predetermined time intervals and LCD contents in the receptor chamber were determined by HPLC and the release profile of pure LCD was used as a reference for better evaluation of the profiles. Sink conditions were maintained in the receptor compartment during the *in vitro* release studies. Each experiment was repeated three times.

In vitro release kinetics

Release kinetics were investigated using the software DDSolver in order to evaluate the mechanism of drug release from nanoparticles.[19]

RESULTS AND DISCUSSION

Different methods were used to prepare chitosan nanoparticles. The method chosen depended on factors such as particle size, thermal and chemical stability of the active agent, reproducibility of the release profiles, stability of the final product, and residual toxicity associated with the final product.[11]

Spray drying is a well-known technique to produce powders, granules, or agglomerates from mixtures of drug and excipient solutions as well as suspensions.[15] In the present study, spray drying was chosen for preparing chitosan nanoparticles since it does not involve toilsome procedures and avoids the use of harsh cross-linking agents and organic solvents that might trigger chemical reactions with the active agent.[11] The compositions of the chitosan nanoparticles prepared are given in Table 2.

Characterization of nanoparticles

Morphology

SEM images of pure LCD and polymeric nanoparticles are given in Figure 1. The images showed that all formulations prepared

Table 2. Compositions of nanoparticles prepared

Code	Chitosan (g)	LCD (g)	Acetic acid solution (2%, v/v, mL)	Methanol (mL)
Placebo	1	-	120	120
F-1	1	0.05	120	120
F-2	1	0.1	120	120

LCD: Levocetirizine dihydrochloride

were spherical.[5] The placebo nanoparticles' images resembled deflated balloons with wrinkled surfaces (Figure 1b), while the LCD-loaded spray-dried formulations demonstrated spherical shapes with the general morphology of spray-dried amorphous materials.[12,20] The crystalline structure of LCD was not observed in the formulations, indicating successful incorporation of LCD into polymeric matrices.

Particle size and zeta potential

Mean particle size, PI, and zeta potential values of the chitosan nanoparticles are presented in Table 3. The particle size and size distribution of nanoparticles play a key role in their adhesion and interaction with cells.[7] Particle sizes of the nanoparticles were 521.70±8.50 nm and 538.46±5.74 nm for F-1 and F-2, respectively. It was found that the decrease in the amount of LCD in nanoparticles was in parallel with the relative decrease in average particle size.[21] PI values were used to define the particle size distribution. All prepared nanoparticles were nanometer sized and the size distributions were relatively monodisperse with PI values of 0.512±0.090 and 0.498±0.074 for F-1 and F-2, respectively. PI values higher than 0.7 are indicative of a very large particle size distribution.[22,23] All nanoparticles prepared in the present study had PI values lower than 0.7; therefore, particle size distribution was uniform.

The span index measures the width of the particle size distribution, as described in the literature.[24] Formulations show a relatively narrow particle size distribution (span index <1). The narrower size distribution reported previously was confirmed by the span values, i.e. the lower span the narrower the particle size distribution.[17] Zeta potential is a scientific notion for electrokinetic potential in colloidal systems and is one of the most important properties, playing a major role in the efficiency of nanomedicine. Zeta potential can affect the physical and pharmacokinetic properties of nanosystems in the body or may affect the phagocytosis of nanoparticles in the blood stream.[25] The results showed that zeta potentials were

25.7±1.8 mV and 25.9±2.5 mV for F-1 and F-2, respectively, which may be attributed to the positive charges on polymeric matrices, indicating adequate physical stability. Considering negatively charged cell membranes, cationic nanoparticles have great potential in the enhancement of internalization with the cells and also on their uptake.[15,26]

Differential scanning calorimetry

Thermodynamic variations related to morphological changes during and after the formulation steps can be detected by thermal analysis.[27] Figure 2 displays the thermal behavior of the LCD and nanoparticles prepared. Pure LCD demonstrated an endothermic peak at 228°C, showing a crystalline structure.[28] According to DSC analyses, no endothermic peaks were revealed in the thermograms of the nanoparticles prepared, showing the amorphous state of the polymeric lattice. The disappearance of LCD peaks in all thermograms of nanoparticles prepared indicated that LCD was molecularly dispersed in the polymeric structure.[7,21,23]

Fourier transform infrared spectrophotometry

FT-IR spectroscopy reveals information about the molecular interactions of chemical components and is beneficial for assessing microstructural changes in the polymeric structure.[29]

The FT-IR spectrum of LCD showed bands assigned to the aromatic -CH (3110-3000 cm^{-1}) and aliphatic -CH$_2$ (2985.6-2914.2 cm^{-1}). While the OH dimer of the amino-carboxylic acid appeared at 2628.98 cm^{-1}, the tertiary amine salt was observed at 2349.30 cm^{-1} (Figure 3). The absorption bands at 1745.58 cm^{-1} and 1600.32 cm^{-1} were a result of the carbonyl group and phenyl nucleus skeletal stretching, respectively. The presence of two adjacent benzene rings was shown at 844.8-808.1 cm^{-1}. While

Table 3. Mean particle size, PI, zeta potential of formulations prepared (n=3)

Code	Particle size (nm) ± SE	PI ± SE	Span values ± SD	Zeta potential (mV) ± SE
Placebo	487.42±7.25	0.426±0.085	0.782±0.058	24.3±2.1
F-1	521.70±8.50	0.512±0.090	0.992±0.073	25.7±1.8
F-2	538.46±5.74	0.498±0.074	0.855±0.081	25.9±2.5

PI: Polydispersity index, SE: Standard error

Figure 1. Scanning electron microscope images of pure LCD and formulations; a) LCD, b) placebo, c) F-1, d) F-2

LCD: Levocetirizine dihydrochloride

Figure 2. Differential scanning calorimetry thermograms of pure LCD and formulations; a) LCD, b) placebo, c) F-1, d) F-2

LCD: Levocetirizine dihydrochloride, SD: Standard deviation

the carboxylic C-O bond frequency was observed at 1463-1263 cm^{-1}, the aliphatic chain C-O bond in $CH_2CH_2OCH_2COOH$ appeared at 1180.4 cm^{-1} and at 758 cm^{-1}.[30] The placebo formulation showed similar absorption bands with pure chitosan. The FT-IR spectrum of the placebo formulation showed characteristic absorption bands at 3352, 2918, and 2850 cm^{-1}, which represent -OH, $-CH_2$, and CH_3 aliphatic groups, and bands at 1558 and 1417 cm^{-1} represent the -NH group bending vibration and vibrations of the -OH group of the primary alcohol, respectively. The amino group has a characteristic band at 3400-3500 cm^{-1} that is concealed by the broad absorption band of the -OH group.[31] Distinctive peaks of LCD were not seen in the spectra of F-1 or F-2 formulations, indicating the molecular dispersion of LCD in the polymeric matrices, which was supported by the DSC results.[7] The absence of LCD distinctive peaks confirmed encapsulation of the drug within the polymeric structure.[6]

Nuclear magnetic resonance spectroscopy

The physicochemical properties of nanoparticles can be identified by NMR analysis in a variety of dosage forms to elucidate the status of active agent incorporated into matrices, its molecular mobility, and molecular interactions between the active agent and the excipients.[12] Peaks appeared in the broad multiplet between 7 and 8 ppm belonging to peaks of 16 aromatic CH protons and 2 NH protons (Figure 4).[32] A singlet was observed at 3.33 ppm for the methyl diphenyl CH proton. A triplet at 3.83 ppm was obvious due to four protons on the acyclic CH_2 groups. Another singlet at 3.51 ppm with two protons was shown for the CH_2 in CH_2CH_2O entity. The CH_2 in the CH_2COOH group appeared as a singlet at 3.73 ppm. A very weak singlet was present at 10.6 ppm for the one proton of the carboxylic acid group.[33] Some characteristic peaks of LCD were found also in the spectra of nanoparticle formulations, indicating successful incorporation of drug into the nanoparticles with no chemical changes.[34] The data were also supported by the DSC and FT-IR results.

Determination of LCD

The analytical process validation method of the International Harmonization Committee was used in the present study. The method was validated for linearity, accuracy, precision, sensitivity, and specificity with reference to the guidelines.[35] The separation and resolution of the LCD from formulations could be achieved using a mixture of acetonitrile:water:1 M sulfuric acid (93:66:4, v/v/v) as the mobile phase with UV detection at 230 nm.[18] The calibration curve was constructed by plotting the peak area ratio (y) of the LCD concentration. The linearity of the method was examined in the range of 2.5-250 $\mu g.mL^{-1}$ and the calibration curve was chosen in this range (Figure 5). Good fit of the equation was found, y=2398.3252x+6416.2523, with a correlation coefficient of 0.9996. The limit of detection (LOD) and limit of quantification (LOQ) values were 0.7968 $\mu g.mL^{-1}$ and 2.4146 $\mu g.mL^{-1}$, respectively. Accuracy is the similarity of the


Figure 3. Fourier transform infrared spectra of pure LCD and formulations; a) LCD, b) placebo, c) F-1, d) F-2

LCD: Levocetirizine dihydrochloride

Figure 4. Nuclear magnetic resonance spectra of pure LCD and formulations; a) LCD, b) placebo, c) F-1, d) F-2

LCD: Levocetirizine dihydrochloride

Figure 5. Calibration curve of levocetirizine dihydrochloride

LCD: Levocetirizine dihydrochloride

Table 4. Accuracy and recovery results

LCD (µg.mL⁻¹)	Recovery (µg.mL⁻¹)	Recovery (%)	SE	RSD
5	4.9039	98.0775	0.7582	1.3391
50	50.0427	100.0855	1.4125	2.4445
250	248.8017	99.5207	0.1239	0.2157

SE: Standard error; RSD: Relative standard deviation, LCD: Levocetirizine dihydrochloride

Table 5. Interday and intraday precision results

LCD (µg. mL⁻¹)	Intraday (n=3)				Interday (n=9)
		Day 1	Day 2	Day 3	
5	Mean area	18466	18137	18203	18269
	SD	0.0981	0.0885	0.0666	0.0725
	RSD	1.9535	1.8111	1.3560	1.4680
50	Mean area	132707	132835	12858	131353
	SD	0.2954	0.8360	0.6790	1.0241
	RSD	0.5610	1.5860	1.3336	1.9660
250	Mean area	609100	610793	603723	607842
	SD	0.4775	0.7398	0.7237	1.5391
	RSD	0.1900	0.2936	0.2906	0.6137

SE: Standard error; RSD: Relative standard deviation, LCD: Levocetirizine dihydrochloride, SD: Standard deviation

test results obtained by the analytical method to the true values. It was reported that recovery values must be in the range of 98%-102% to decide on the accuracy of the method used. The HPLC method used in this study yielded high recovery values (98%-100%) (Table 4), which indicated the accuracy of the method used. Measurements obtained with three different concentrations (low, medium, and high) evaluating repeatability and reproducibility of the analytical method used seem to verify the precision of the method since the percentage of relative standard deviation (RSD) was below 2%, which is within the targeted interval (Table 5).[36] Meanwhile this method was specific for the determination and quantification of LCD. The method validation conducted proved the accuracy, reliability, and specificity of the method. It was found that all the results of the present coefficient of variation are below 2%, showing the method was valid.[37,38]

Encapsulation efficiency

The EE is the percentage of the amount of the drug loaded into polymeric matrices. In the present study, EE % was 71.37±1.32 and 67.328±2.09 (EE % ± SE) for F-1 and F-2, respectively. Drug-polymer composition is most likely one of the reasons for the *in vitro* release rate; however, it seems that a complex phenomenon between active agent and polymer molecules may occur, including entrapment of drug within the polymeric network and the adsorption of drug molecules on the surface of polymeric matrices as a result of electrostatic adhesion.[39,40]

In vitro drug release

Dissolution testing has been recognized as an important tool for both drug development and quality control.[41] It can be used not only as a primary tool to monitor the consistency and stability of drug products but also as a relatively rapid and inexpensive technique to predict *in vivo* absorption of a drug formulation.[19] The release profiles obtained from chitosan nanoparticles are given in Figure 6. The release profile of pure LCD was used as reference. LCD release from nanoparticles was much slower than that of its pure form, showing a time-dependent release manner in release media. Moreover, there was no significant


Figure 6. *In vitro* release profiles of levocetirizine dihydrochloride from nanoparticles prepared (n=3) (mean ± standard error)

difference between F-1 and F-2 formulations as stated by the release profiles (p>0.05).[21] The release rate was not affected significantly by increasing the amount of LCD used in the nanoparticles. Moreover, drug release was extended more than 2-fold with nanoparticles, which enhances their possible use for better treatment.

In vitro release kinetics

Quantitative evaluation of drug dissolution characteristics is of great interest to pharmaceutical scientists. Drug release data were evaluated using many mathematical and statistical parameters.[19]

Fitting *in vitro* release profiles to mathematical models describing drug release as a function of time gives valuable data about the *in vivo* release behavior of optimal delivery systems.[42] Therefore, *in vitro* release kinetics were also evaluated for nanoparticles in comparison with pure LCD using DDSolver.[19]

In vitro dissolution data were transferred to DDSolver to determine five important and the most popular criteria. These criteria were based on the coefficient of determination (Rsqr, R^2, or COD), the adjusted coefficient of determination ($R^2_{adjusted}$), the Akaike information criterion (AIC), the model selection criterion (MSC), and n for only Korsmeyer–Peppas models. The highest R^2, $R^2_{adjusted}$, and MSC values and the lowest AIC values were used for the evaluation of the best fitted models.[19,43] Zero-order kinetics, first-order kinetics, Higuchi, Hixson–Crowell, Korsmeyer–Peppas, and Hopfenberg models were selected for evaluation in DDSolver. The majority of these models usually have nonlinear equations. DDSolver has been developed to utilize the hardships encountered in comparing free profiles with several different dissolution parameters for eliminating many experimental mistakes and the other mistakes due to the user.[19] The R^2, $R^2_{adjusted}$, MSC, and AIC values obtained as a result of applying *in vitro* release study data to different kinetic models using DDSolver are shown in Table 6. Release of pure LCD fit best the first-order model, where drug release is concentration dependent. *In vitro* release from chitosan nanoparticles fit best the Korsmeyer–Peppas model according to all the criteria. This model indicates diffusion controlled release from a polymeric matrix nano-system developed.[9,23] 'n' is the diffusional release exponent that could be used to characterize the different release mechanisms [n≤0.45 (Fickian diffusion), 0.45<n<1 (anomalous transport), and n=1 (case II transports; i.e. zero-order release)]. The Korsmeyer–Peppas equation proposed that release of LCD from the polymeric matrices was through Fickian diffusion (n=0.290 and n=0.420 for F-1 and F-2, respectively). This information suggests that LCD release from the nanoparticles was through diffusion.[44]

CONCLUSION

In this study, LCD was used as a model drug to be entrapped in a natural biodegradable material (chitosan) using spray drying. The results of analyses demonstrated that nanometer-sized spherical nanoparticles were achieved with this technique. Moreover, the nanoparticles showed a narrow size distribution, cationic characteristic, and relatively high EE. Solid state characterization studies such as DSC, FT-IR, and ¹H-NMR confirmed the successful incorporation into the polymeric matrices. It was shown that all nanoparticles displayed a prolonged release pattern without a burst effect in comparison

Table 6. Release kinetic modeling of levocetirizine dihydrochloride-loaded nanoparticles

Code	Model and equation	Evaluation criteria					
		k	R^2	$R^2_{adjusted}$	AIC	MSC	n
LCD	Zero-order model* $F=k_0*t$	2.100	-8.446	-8.446	120.841	-2.427	-
F-1		1.682	-0.180	-0.180	101.939	-0.347	-
F-2		1.745	-0.335	-0.335	103.943	-0.471	-
LCD	First-order model* $F=100*[1-Exp(-k_1*t)]$	0.805	0.932	0.932	66.594	2.504	-
F-1		0.060	0.745	0.745	85.068	1.186	-
F-2		0.068	0.741	0.741	85.904	1.169	-
LCD	Higuchi model* $F=k_H*t^{0.5}$	19.106	-3.304	-3.304	112.194	-1.641	-
F-1		13.298	0.794	0.794	82.722	1.400	-
F-2		13.931	0.738	0.738	86.047	1.156	-
LCD	Hixson–Crowell model* $F=100*[1-(1-k_{HC}*t)^3]$	0.027	-4.977	-4.977	115.807	-1.970	-
F-1		0.014	0.565	0.565	90.958	0.651	-
F-2		0.016	0.521	0.521	92.659	0.555	-
LCD	Korsmeyer–Peppas* $F=k_{KP}*t^n$	97.701	-0.321	-0.468	101.200	-0.642	0.000
F-1		25.722	0.929	0.921	73.074	2.277	0.290
F-2		20.211	0.843	0.826	82.370	1.490	0.420
LCD	Hopfenberg model* $F=100*[1-(1-k_{HB}*t)^n]$	0.081	0.132	0.035	96.584	-0.222	3.000
F-1		0.014	0.565	0.517	92.958	0.469	3.000
F-2		0.016	0.522	0.469	94.652	0.374	3.000

*In all models, F is the fraction (%) of drug released in time t, k_0: zero-order release constant, k_1: first-order release constant, k_H: Higuchi release constant, k_{HC}: Hixson-Crowell release constant k_{KP}: release constant incorporating structural and geometric characteristics of the drug-dosage form, n: is the diffusional exponent indicating the drug-release mechanism, F_0 is the initial fraction of the drug in the solution resulting from a burst release, k_{HB}: Hopfenberg release constant, LCD: Levocetirizine dihydrochloride

with the pure drug. According to the criteria, formulations were fitted to the Korsmeyer–Peppas model demonstrating the diffusion mechanism of polymeric matrices. *In vitro* studies showed that cationic chitosan nanoparticles containing LCD are effective carrier candidates for reducing local irritation to GI membranes and other side effects and optimizing plasma drug concentration improving bioavailability and protection of sensitive drugs against light, thus also improving their stability. However, *in vivo* analyses are required for a final decision to be made.

ACKNOWLEDGEMENTS

Conflicts of interest: No conflict of interest was declared by the authors.

REFERENCES

1.   Prabhu P, Malli R, Koland M, Vijaynaryana K, D'Souza U, Harish NM, Shastry CS, Charyulu RN. Formulation and evaluation of fast dissolving films of levocetirizine dihydrochloride. Int J Pharm Investig. 2011;1:99-104.

2.   Goindi S, Kumar G, Kaur A. Novel flexible vesicles based topical formulation of levocetirizine: *in vivo* evaluation using oxazolone-induced atopic dermatitis in murine model. J Liposome Res. 2014;24:249-257.

3.   Takahashi H, Ishida-Yamamato A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal- and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol. 2004;29:526-532.

4.   El-Say KM, El-Hewl ARM, Ahmed OAA, Hosny KM, Ahmed TA, Kharshoum RM, Fahmy UA, Alsawahli M. Statistical optimization of controlled release microspheres containing cetrizine hydrochloride as a model for water soluble drugs. Pharm Dev Technol. 2015;20:738-746.

5.   Li F, Ji R, Chen X, You B, Pan Y, Su J. Cetrizine dihydrochloride loaded microparticles design using ionotropic cross-linked chitosan nanoparticles by spray-drying method. Arch Pharm Res. 2010;33:1967-1973.

6.   Vino S, Preethi LR, Gopika M, Ghosh AR. Controlled release formulation of levocetirizine dihydrochloride by casein microparticles. Afr J Pharm Pharmaco. 2013;7:1046-1053.

7.   Yurtdaş-Kırımlıoğlu G, Yazan Y. Formulation and *in vitro* characterization of polymeric nanoparticles designed for oral delivery of levofloxacin hemihydrate. Euro Int J Sci Technol. 2016;5:148-157.

8.   Foged C, Brodin B, Frokjaer S, Sundblad, A. Particle size and surface charge affect particle uptake by human dendritic cells in an *in vitro* model. Int J Pharm. 2005;298:315-322.

9.   Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan - a versatile semi-synthetic polymer in biomedical applications. Prog Polym Sci. 2011;36:981-1014.

10. Vino S, Paryani P, Sajitha LS, Ghosh AR. Formulation and evaluation of chitosan beads of levocetirizine dihydrochloride. J Appl Pharm Sci. 2012;2:221-225.

11. Agnihotri SA, Mallikarjuna NN, Aminabhavi TA. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100:5-28.

12. Başaran E, Yenilmez E, Berkman MS, Büyükköroğlu G, Yazan Y. Chitosan nanoparticles for ocular delivery of cyclosporine A. J Microencapsul. 2014;31:49-57.

13. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004;274:1-33.

14. Re M. Formulating drug delivery systems by spray drying. Dry Technol. 2006;24:433-446.

15. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm. 1999;187:53-65.

16. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm. 2006;62:295-305.

17. Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q_{10} - development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm. 2007;67:141-148.

18. USP (The United States Pharmacopeia), Levocetirizine Dihydrochloride, 2017. Available from: http://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/iras/levocetirizine-dihydrochloride-m3460-ira.pdf

19. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S. DDSolver: an add-in program for modelling and comparison of drug dissolution profiles. AAPS Journal. 2010;12:263-271.

20. Sormoli ME, Islam MIU, Langrish TAG. The effect of chitosan hydrogen bonding on lactose crystallinity during spray drying. J Food Eng. 2012;108:541-548.

21. Yenilmez E, Yurtdaş-Kırımlıoğlu G, Şenel B, Başaran E. Preparation, characterization and *in vitro* evaluation of dirithromycin loaded Eudragit RS 100 nanoparticles for topical application. Lat Am J Pharm. 2017;36:2203-2212.

22. Lopedota A, Trapani A, Cutrignelli A, Chiarantini L, Pantucci E, Curci R, Manuali E, Trapani G. The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur J Pharm Biopharm. 2009;72:509-520.

23. Öztürk AA, Yenilmez E, Arslan R, Şenel B, Yazan Y. Dexketoprofen trometamol-loaded Kollidon® SR and Eudragit® RS 100 polymeric nanoparticles: formulation and *in vitro-in vivo* evaluation. Lat Am J Pharm. 2017;36:2153-2165.

24. Tan CP, Nakajima M. β-Carotene nanodispersions: preparation, characterization and stability evaluation. Food Chem. 2005;92:661-667.

25. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems - a review (part 1). Trop J Pharm Res. 2013;12:255-264.

26. Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliver Rev. 2007;59:411-418.

27. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm. 2005;304:231-238.

28. Choudhury P, Deb P, Dash S. Formulation and statistical optimization of bilayer sublingual tablets of levocetirizine hydrochloride and ambroxol hydrochloride. Asian J Pharm Clin Res. 2016;9:228-234.

29. Saito Y, Iwata T. Characterisation of hydroxyl groups of highly crystalline-chitin under static tension detected by FT-IR. Carbohydr Polym. 2012;87:2154-2159.

30. Kenawi IM, Barsoum BM, Youssef MA. Drug-drug interaction between diclofenac, cetirizine and ranitidine. J Pharm Biomed Anal. 2005;37:655-661.

31. Sionkowska A, Wisniewski M, Skopinska J, Kennedy CJ, Wess TJ. Molecular interactions in collagen and chitosan blends. Biomaterials. 2004;25:795-801.

32. Ali SM, Upadhyay SK, Maheshwari A. NMR spectroscopic study of inclusion complexes of cetirizine dihydrochloride and β-cyclodextrin in solution. Spectroscopy. 2007;21:177-182.

33. Shamshad H, Arayne MS, Sultana N. Spectroscopic characterization of *in vitro* interactions of cetirizine and NSAIDS. J Anal Sci Technol. 2014;5:1-8.

34. Yurtdaş-Kırımlıoğlu G, Yazan Y. Development, characterization and *in vitro* release characteristics of rabeprazole sodium in halloysite nanotubes. Euro Int J Sci Technol. 2016;5:99-109.

35. ICH, Q2R1 2005. Harmonised Tripartite Guideline, Validation of Analytical Procedure: Text and Methodology, Complementary Guideline on Methodology, in: Proceedings of the International Conference on Harmonization, Canada. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-2-r1-validation-analytical-procedures-text-methodology-step-5_en.pdf

36. Shabir GA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatogr A. 2003;987:57-66.

37. Yurtdaş-Kırımlıoğlu G, Yazan Y. Determination of gamma-aminobutyric acid by HPLC: its application to polymeric nanoparticles and stability studies. Int J Develop Res. 2016;6:8277-8282.

38. Öztürk AA, Yenilmez E, Yazan Y. Development and validation of high performance liquid chromatography (HPLC) modified method for dexketoprofen trometamol. Euro Int J Sci Technol. 2017;6:33-41.

39. Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri FK, Alaei-Beirami M. Naproxen-Eudragit® RS100 nanoparticles: preparation and physicochemical characterization. Colloids Surf B Biointerfaces. 2011;83:155-159.

40. Thagele R, Mishra A, Pathak AK. Formulation and characterization of clarithromycin based nanoparticulate drug delivery system. Int J Pharm Life Sci. 2011;2:510-515.

41. Zuo J, Gao Y, Bou-Chacra N, Löbenberg R. Evaluation of the DDSolver software applications. Biomed Res Int. 2014;ArticleID204925:1-9.

42. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-133.

43. Victor OB, Francis OA. Evaluation of the kinetics and mechanism of piroxicam release from lipophilic and hydrophilic suppository bases. Int J ChemTech Res. 2017;10:189-198.

44. Sharma UK, Verma A, Prajapati SK, Pandey H, Pandey AC. *In vitro, in vivo* and pharmacokinetic assessment of amikacin sulphate laden polymeric nanoparticles meant for controlled ocular drug delivery. Appl Nanosci. 2015;5:143-155.